Podcasts about Melanoma

Popular media leverage weak study to criticize RFK Jr.'s rethink of standard recommendations for saturated fat avoidance; Poor quality plant-based diets hike cardio risk; A listener complains his lp(a) is going up with age despite his healthy diet, lifestyle; Scientists pinpoint cocoa ingredient that slows aging; Berry proanthocyanidins preserve brain power; Tattooing may promote inflammation, undermine immunity.

Q-BANK: https://patreon.com/highyieldfamilymedicineIntro (0:35),Venous leg ulcers (1:45),Arterial (ischemic) ulcers (2:58),Diabetic foot ulcers (4:42),Pressure injuries (6:10),Pyoderma gangrenosum (8:24),Burns (9:36),Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (13:12),Warfarin necrosis (14:33),Necrotizing fasciitis (15:21),Rocky Mountain Spotted Fever (16:22),Erythema nodosum (17:35),Lipoma (19:08),Epidermal inclusion cyst (20:00),Dermatofibroma (20:51),Cherry hemangiomas (21:52),Seborrheic ketatosis (22:37),Actinic keratosis (23:41),Basal cell carcinoma (24:47),Squamous cell carcinoma (26:24),Melanoma (28:05),Kaposi sarcoma (30:29),Mycosis fungoides (31:26),Practice questions (32:50)

Today's guest is Tessa Parry-Wingfield, global communications consultant, public speaker, and survivor of ocular melanoma, a very rare form of eye cancer that affects about 6 people per million annually. She has found purpose in her adversity and ironically "sees life clearly" despite her vision issues.We talk about learning to live with a prosthetic eye and monocular vision, the challenges of rare cancers, eye and vision health (see your eye doctor regularly), finding purpose and clarity post diagnosis, and so much more!Resources:Tessa's Website: Tessa Parry-Wingfield | Speaker + Storyteller | Seeing life clearly |Tessa's Instagram: https://www.instagram.com/seeing_life_clearly/Tessa's LinkedIn: Tessa Parry-Wingfield | LinkedInFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Commentary by Dr. Avirup Guha.

Veterinarian David Levine is a boarded surgeon who frequently deals with equine skin issues such as melanoma. Learn what melanomas are, how to recognize them, and what can be done to treat them.My Senior Horse - Episode 35 Guests and Links:Guest: Dr. David Levine, DVMConnect with Host: Kimberly S. Brown of Editorial Director of My Senior Horse | Email Kim (kbrown@equinenetwork.com) | Follow Kim on LinkedIn (@kimberlylsbrown)

Did Cankles Caligula forget he has a son with Melanoma or is "her son" just not his? MAGAT House introduces silly excuse for a healthcare bill. More photos from the Epstein Estate and the ones yet to come are described as deeply disturbing. ICE goon gets taken to police station after attempting to kidnap immigrants. Maryland court allows sexual abuse lawsuit against Linda McMahon go forward. 

This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.Studies:LITESPARK-15IMPRESS-Norway trialAbstract 1510M0BNT111 (NCT04526899)Safe Stop TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Melanoma used to have almost no effective treatment options. Now? Immunotherapy is changing lives — and Oxford's Dr. Mark Middleton joins us to unpack the science, the turning points, and the innovations reshaping melanoma care.In this episode, he reflects on decades of research — from the early trials that taught researchers what not to do, to the breakthroughs in checkpoint inhibition and precision approaches that dramatically improved outcomes. We also dive into MyMelanoma, a nationwide effort gathering real-world patient data to answer questions traditional trials often leave behind.Takeaways:What researchers learned from early immunotherapy trial failures — and how those lessons shaped today's strategies The evolving science behind checkpoint inhibitors and why certain patients respond more durably than othersHow MyMelanoma is uncovering insights on risk, survivorship, lifestyle factors, and real-world outcomes at scale The future of melanoma treatment, including biomarkers, combinatorial approaches, and better trial designs

Dr. Juan Carlos Samamé, oncólogo médico de Lima, Perú, y vicepresidente de la Latin American Breast Cancer Association (LABCA), recibe a la Dra. Cristina Saura, oncóloga médica del Hospital Vall d'Hebron e investigadora principal del grupo de Cáncer de Mama y Melanoma del VHIO en Barcelona, España, con quien discutirá los principales aspectos del estudio DESTINY-Breast09.Dentro de su conversación, se plantearon las siguientes preguntas:¿Cómo se diseñó el estudio DESTINY-Breast09 y cuál fue su objetivo principal dentro del escenario de primera línea para cáncer de mama HER2 positivo metastásico?¿Qué características clínicas definieron a la población incluida en el estudio y cómo se distribuyeron las pacientes según enfermedad de novo, recaída y estatus hormonal?Respecto a los objetivos del estudio, ¿qué objetivos primarios se evaluaron y cuál fue el resultado principal en términos de supervivencia libre de progresión?En comparación con el estudio CLEOPATRA, ¿qué diferencias clave existieron entre las poblaciones tratadas y qué elementos podrían explicar la evolución terapéutica del estándar en cáncer de mama HER2 positivo?En el contexto del doble bloqueo con trastuzumab y pertuzumab, ¿cómo interpreta la eficacia histórica de CLEOPATRA frente a los resultados recientes de DESTINY-Breast09 y el papel de trastuzumab deruxtecan en primera línea?Considerando que muchas pacientes en CLEOPATRA permanecieron en mantenimiento durante años con excelente tolerancia, ¿cómo ha sido la experiencia clínica en términos de calidad de vida y duración del doble bloqueo?En pacientes largas supervivientes con THP (Taxano + Trastuzumab + Pertuzumab), ¿qué criterios clínicos suelen condicionar la continuidad del tratamiento y en qué escenarios se plantea la suspensión?Entre otras. Fecha de grabación: 04 de noviembre de 2025. Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Does having darker skin really protect you from skin cancer? Can you imagine getting a Pap smear every single day for 21 years just to help your husband’s research? And, what do you do if your vagina involuntarily “clenches” during sex. In this episode, we speak to Professor Georgina Long, Medical Director of Melanoma Institute Australia (MIA) and 2024 Australian of the Year, to decode Australia’s complicated relationship with the sun. We talk about the "ABCDE" rule for checking your moles, whether darker skin tones are at less risk of melanoma and why you should be taking photos of your skin spots.Plus, in Med School, Claire and Dr Mariam pay tribute to the unsung heroines of medical history - from the wife of Dr. Papanicolaou (who underwent daily pap smears for 21 years ) to Anarcha Westcott, the enslaved woman known as the 'mother of modern gynecology', who endured 30 experimental surgeries without anaesthesia.And, in our Quick Consult, Dr Mariam helps a listener named Sarah who is struggling with Vaginismus. We break down exactly what this condition is, why it is a physical reflex rather than "just in your head" and the multidisciplinary team you need to help reclaim your sex life.THE END BITS All your health information is in the Well Hub. If you've been putting off a skin check, this is your sign to book it. For more information on sun safety, visit the Cancer Council. We understand that conversations about cancer can be difficult, whether you're navigating your own diagnosis, supporting a loved one, or remembering someone you've lost. If today's episode has brought up difficult feelings, please reach out. The Cancer Council offers a confidential support line staffed by specialist nurses, and you can call them on 13 11 20. For more specific information on the topics we discussed today, organisations like the Cancer Council, the Australian Skin Cancer Foundation, and the Melanoma & Skin Cancer Advocacy Network (MSCAN) provide dedicated advocacy, education and community support for patients impacted by all forms of skin cancer. And if you just need to talk to someone immediately, you can always call Lifeline on 13 11 14. Remember to be kind to yourself, and please don't hesitate to seek support. GET IN TOUCH Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. Support independent women’s media by becoming a Mamamia subscriber CREDITS Hosts: Claire Murphy and Dr Mariam Guest: Professor Georgina Long Senior Producers: Claire Murphy and Sally Best Audio Producer: Scott Stronach Video Producer: Julian Rosario Social Producer: Elly Moore Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional. +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier talked with Proactive's Stephen Gunnion about new clinical data from its phase two melanoma study, known as the SCOPE trial, featuring its lead ImmunoBody candidate, iSCIB1+. L'Huillier highlighted that the trial has achieved the objectives set out for it, confirming the parameters for the company's upcoming registrational phase three study. The findings now provide clarity on dosing, patient population, and trial design. “Our SCOPE study…has met the objectives that we set out for it,” he said. A key point of the discussion focused on the data, which showed a 74% progression-free survival rate at 16 months for iSCIB1+. This compares to 46% at 12 months for the standard of care, which typically includes dual checkpoint inhibitors Ipilimumab and Nivolumab. L'Huillier noted this as a "really strong and durable benefit" on top of existing treatments. He also addressed how iSCIB1+ performed across patient subgroups where existing therapies are typically less effective—such as BRAF, PD-L1 status, and those with prior checkpoint treatment—with results showing clinically meaningful benefit across all. Scancell now plans to begin its phase three trial in late 2026, having received supportive regulatory feedback. L'Huillier also said the data has materially strengthened the company's case for partnering and financing opportunities as part of a dual-track strategy to either partner or proceed independently. Watch the full video for more insights. Like, subscribe, and enable notifications so you never miss an update from Proactive's YouTube channel. #Scancell #Melanoma #CancerResearch #ClinicalTrials #Immunotherapy #iSCIB1 #BiotechNews #Phase3Trial #Oncology #ProactiveInvestors

Welcome to Session 1 of the Eye Believe Survivorship Seminar 2025! This 8:00 AM session features renowned ocular oncologist Dr. MATERIN (Duke Health) as he presents “Yesterday, Today & Tomorrow in Ocular Melanoma.” In this powerful opening session, Dr. Materin walks attendees through:

In this episode, we sit down with Vanessa Tompkins, wife and caregiver to Mike, who has been battling Stage 4 metastasized ocular melanoma. Over the past five years, Vanessa has supported Mike through weekly immunotherapy, four major surgeries—including the removal of his left eye, liver surgery, triple hernia repair, and open-heart surgery—and countless challenges along the way.A registered nurse, former hospice nurse, and current Sexual Assault Forensic Examiner, Vanessa brings professional expertise, personal experience, and unwavering compassion to her role as a caregiver. She is also a mother of three, grandmother of four, and devoted owner of her golden lab, Romeo. Guided by her motto, “One day at a time,” Vanessa shares insights into the realities of caregiving, the emotional resilience required, and the lessons learned in supporting a loved one through a complex and ongoing cancer journey.Tune in to hear her story, practical tips, and heartfelt reflections on the challenges and rewards of being a caregiver.

In this episode, we interview Danny Powell, an ocular melanoma (OM) patient whose tumor was identified early thanks to his eye doctor noticing a change and acting quickly. Danny explains his diagnosis, his treatment with brachytherapy, and how he later discovered that his grandmother also had OM—an extremely rare family connection. This prompted genetic testing, which revealed that Danny carries a BAP1 gene mutation. He discusses what that means for his ongoing care, his decision to join a clinical study, and the importance of regular surveillance scans. Whether you're an OM patient, caregiver, or medical professional, this episode provides practical insight into early detection, genetic risk factors, and patient involvement in research.

Gugs Mhlungu is joined by Dr Bonolo Mushiana, Specialist Dermatologist discussing this year's skin cancer awareness theme, the different types of skin cancer, their causes, treatment and prevention. 702 Weekend Breakfast with Gugs Mhlungu is broadcast on 702, a Johannesburg based talk radio station, on Saturdays and Sundays Gugs Mhlungu gets you ready for the weekend each Saturday and Sunday morning on 702. She is your weekend wake-up companion, with all you need to know for your weekend. The topics Gugs covers range from lifestyle, family, health, and fitness to books, motoring, cooking, culture, and what is happening on the weekend in 702land. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

TJ Sharpe is a stage four melanoma survivor, nationally known patient advocate, keynote speaker, digital health technologist, and consultant to the life sciences industry. Drawing from personal experience and his work in clinical research, TJ empowers healthcare and pharma organizations to prioritize patient-centric approaches to trials, communication, and support. He shares his story to inspire others facing adversity and to promote transformative improvements in healthcare. In this episode of Marketer of the Day, TJ Sharpe joins Robert Plank to recount his journey from being diagnosed with melanoma in his twenties, through a life-threatening recurrence that led him to cutting-edge clinical trials, to his eventual recovery and the launch of his advocacy career. TJ details his navigation of the medical system, the emotional and logistical challenges faced by patients, and how gratitude and support systems are as important as medical interventions. The discussion spotlights the importance of accessible, transparent information, and patient empowerment within clinical research. TJ also describes his consulting work to help organizations incorporate patient voices and streamline drug development for the benefit of all. Quotes: “If you don't know all your options, you're not making the most informed choice for you.” “Finding your ‘ninja'—that support person—makes all the difference in getting through a cancer journey.” “It's not just about surviving cancer, it's about making a difference for millions more who will walk this path.” Resources: Visit TJ Sharpe's Website Connect with TJ Sharpe on LinkedIn

The Naked Scientists welcome the return of a new series of Titans of Science, where the world's scientific, medical, and technological pioneers tell us about the significance of their work. Today's episode features Georgina Long, the director of the Melanoma Institute Australia, who has used groundbreaking techniques to overcome the disease. Melanoma is a type of cancer that is particularly common in Georgina's homeland, and she has been telling Chris Smith how her work has made her one of Australia's most recognisable scientists... Like this podcast? Please help us by supporting the Naked Scientists

Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.

Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.

Dani nos explica cómo funciona la vacuna desarrollada en Argentina para tratar el melanoma. ¿Cómo llegamos a este avance científico tan importante? ¿Todos los melanomas son iguales? Averigualo escuchando esta columna

Can natural herbs aid recovery from anorexia? What an analysis of Hitler's DNA tells us about how genes shaped his personality; Can surgical anesthesia accelerate memory loss?  Bananas could be interfering with your smoothie's health benefits; Not just sun, but pesticides and herbicides increase risk for melanoma; Chemical residues on produce impair male fertility; Proliferation of fast-paced social media videos are dumbing us down; Doctors aren't less resilient, the demands of medicine are just fostering unprecedented levels of physician burnout.

Estas son las noticias de la mañana del lunes 24 de noviembre de 2025

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.

Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.

Key PointsCraig identified his lymph nodes as the most difficult area to treat after the squamous cell carcinoma metastasized into his neck and spread rapidly through his body almost overnight.Black salve treatment was used successfully on two to three dozen skin cancers over several years, with one recurring lesion in the jawline requiring multiple treatments through the soft tissue.Craig's wife noticed a suspicious mole with irregular pattern and color changes, prompting her to urge him to seek medical attention despite his reluctance to visit doctors.Inspiration came from a friend named Mick from Port Lincoln who had laser skin cancer that progressed through multiple surgeries, chemotherapy, and radiation before doctors said they would remove his cheekbone and upper jaw as a final measure.Craig maintained a positive attitude throughout treatment, stating he was confident the natural protocols would work and never feared for his life, unlike many other cancer patients.Multiple lesions appeared simultaneously after waking one night with a line running from a head lesion down to his lymph nodes, creating a half golf ball-sized mass in his neck.Internal bloodroot capsules were taken as part of the treatment protocol, causing approximately 30 lesions to emerge on his back, arms, and legs all at once several weeks later.Rick Simpson oil was consumed at a dosage of two grams daily, taken as suppositories during daytime to maintain functionality and orally before bed mixed with coconut oil for better sleep.Family members expressed resistance and concern about the alternative treatment approach, with some calling him an idiot for thinking he knew better than doctors.Cannabis access in Australia has become easier through decriminalized status in some states and a government medicinal cannabis program, with much product imported from Canada.Comprehensive detox protocols included a clean organic vegan diet with no sugar, castor oil liver detox treatments, coffee enemas, heavy metal detox smoothies with cilantro, and Essiac tea.Craig's partner's 77-year-old mother was diagnosed with stage four lung cancer that had metastasized to her heart lining, with doctors stating there was nothing they could do.Treatment for the partner's mother included Rick Simpson oil mixed with frankincense and myrrh, plus the same vegan diet and detox protocols, along with Fenbendazole and Ivermectin.Eight weeks after starting alternative treatment, scans showed the partner's mother's stage four lung cancer was nearly all gone, with only small scar tissue remaining. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Visuals: https://getbehindthebillboard.com/episode-97-andy-clough-richard-mcgrannGood things come to those who wait … and we've been waiting a while for Andy Clough & Richard McGrann, but it was thoroughly worth it. Andy & Rich are one of adland's most brilliant and prolific teams, creating iconic award-winning work wherever they've worked. RKCR / Y&R, BBH, AMVBBDO, adam&eveDDB and Neverland have all benefited from their passion for big ideas, superbly executed. They've won awards wherever they've been, including 5 Grand Prix for their emotive ‘The Last Photo' campaign for CALM, placing them amongst the world's most awarded creatives at D&AD and Cannes.In a packed episode, we talked about The Times ‘Biggest For Sport' campaign and got a sneak peek into Andy's notebook and his sketches which were incredibly close to the finished work.For The Last Photo we discovered the inspiration for the big idea came in part from a Google search for ‘depression / suicide'. Every result had people sad, head in hands, in a dark place. The question was asked, what if people looked happy? Like a weight had been lifted, because they had decided to take the next step. This lead to the line ‘Suicide doesn't always look suicidal' and the concept of the last photo featuring real people. It's an incredibly moving story and a worthy follow up to the previous year's Project84 from Ant & Mike.We went into the wild with Whiskas, Feeding Your Cat's Instinct, which naturally won an outdoor Lion ;-)While for The Economist, for once we didn't discuss white headlines out of red, instead a thought provoking piece of DOOH on the subject of assisted suicide.Another important project was for Melanoma, more great crafting a simple graphic idea. And of course we found out how pot holes help create a great poster campaign for Pot Noodle.Gents, it was a total pleasure. So much amazing work for such a range of brands and projects, a tour de force in the great outdoors. Thank you so much.Thanks to our sponsorsBauer Media OutdoorView2FillSuper OptimalGAS Music

Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy. Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. And our objective for patients is to pick up the patients that are unresponsive to current therapies or that respond for a short period of time to improve the overall survival through developing therapies that give a good duration of response, potent immune responses, but are also safe for patients." "Perhaps before I share results from the studies, I should step back a little bit and just tell you about the platform and the product that the data has arisen for. At Scancell, we're developing these off-the-shelf. The data that we're about to talk about comes from our lead program, which is an off-the-shelf DNA immunotherapy called Immunobody, that's the name that we use for it. And it's different from the personalized therapies, the personalized vaccines that require an individual to give a tumor sample. And then there's sequencing and manufacturing for the individual there. This is off the shelf." #Scancell #Immunobody #Immunotherapy #Cancer #Oncology #Melanoma #Biotech scancell.co.uk Download the transcript here

Phil L'Huillier, CEO of Scancell, has developed an off-the-shelf DNA immunotherapy designed to generate a potent and durable immune response against advanced melanoma in patients who are unresponsive to current therapies. Their lead candidate showed significant benefit when added to standard of care checkpoint inhibitors, improving duration of response without adding side effects or toxicity. Patient selection in future trials will use a blood test to identify the immune types that can be expected to respond best to the therapy. Phil explains, "Perhaps first and foremost, Scancell is a clinical-stage company developing novel active immunotherapies for patients. And our objective for patients is to pick up the patients that are unresponsive to current therapies or that respond for a short period of time to improve the overall survival through developing therapies that give a good duration of response, potent immune responses, but are also safe for patients." "Perhaps before I share results from the studies, I should step back a little bit and just tell you about the platform and the product that the data has arisen for. At Scancell, we're developing these off-the-shelf. The data that we're about to talk about comes from our lead program, which is an off-the-shelf DNA immunotherapy called Immunobody, that's the name that we use for it. And it's different from the personalized therapies, the personalized vaccines that require an individual to give a tumor sample. And then there's sequencing and manufacturing for the individual there. This is off the shelf." #Scancell #Immunobody #Immunotherapy #Cancer #Oncology #Melanoma #Biotech scancell.co.uk Listen to the podcast here

In this inspiring episode of the Eye Believe Podcast

Drs. Kavita Vakharia, surgical oncologist from City of Hope, Dr Sara Bateni, surgical oncologist at University of Alabama at Birmingham, Dr Nikhil Khushalanai, medical oncologist at the H. Lee Moffitt Cancer Center and James Jakub, surgical oncologist at the Mayo Clinic, Florida, discuss their current practice regarding multidisciplinary management of melanoma with a focus on the role of adjuvant systemic therapy for stages IIB, IIC and IIIA disease.

It started with a routine checkup, then she heard the word “cancer.” We follow one woman's journey who was diagnosed with breast cancer and then melanoma. 

In this episode of Beyond the Clinic: Living Well with Melanoma, Dr. Samantha Siegel is joined by Katie Ostrovsky and Cheryl Marker from the MelaHomies community.Cheryl, diagnosed with Stage I melanoma in 2023, shares how she turned to online groups for education and support when her medical team left her with more questions than answers. Katie, a Stage IV survivor now, 11 years cancer-free, reflects on the emotional and practical challenges of survivorship — and how building the Mela Homies helped transform isolation into connection.Together, they explore the power of peer support, the gaps in survivorship care, and why community is just as vital as treatment.

Skin cancer can be aggressive, and it doesn't always stay on the surface. Hear one woman's powerful story of choosing surgery and immunotherapy to fight back.

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses. Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 

Join us for an educational discussion on Navicular Syndrome with Dr. Adam Cayot Keatan Rumsey, a licensed massage therapist, and Micheala Godshall, an equine massage therapist join us tonight from Be Well Holistic Massage Wellness Center, P.A. Do you know Art History? With us tonight is Natalie Cowan, owner of Standardbred horse Art History, winner of over 500k! The best treatment for summer sores, miracle hoof paste, the best in natural healing sprays and a new product coming soon with Kaelyn Moseler from Kawell USA

Redheads are bullied, fetishized, and medically misunderstood. Jessica Wynn is here to color in the facts about being a ginger on this Skeptical Sunday!Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we're joined by writer and researcher Jessica Wynn!Full show notes and resources can be found here: jordanharbinger.com/1219On This Week's Skeptical Sunday:The MC1R gene mutation causes red hair, pale skin, and freckles, but also influences pain processing, drug metabolism, and other biological functions throughout the body.Redheads experience pain differently — they tolerate electric shocks better but are more sensitive to heat and cold, requiring adjusted medical treatment approaches.Redheads have significantly higher melanoma risk because they produce less protective melanin, making sunscreen essential and frequent sun exposure dangerous.Redheads face ongoing discrimination and fetishization — from childhood bullying to adult harassment — despite red hair being a normal genetic variation affecting one to two percent of the population.Research on redheads' unique genetics is advancing pain treatment for everyone. Understanding genetic diversity helps medicine better serve all patients, not just those with red hair.Connect with Jordan on Twitter, Instagram, and YouTube. If you have something you'd like us to tackle here on Skeptical Sunday, drop Jordan a line at jordan@jordanharbinger.com and let him know!Connect with Jessica Wynn at Instagram and Threads, and subscribe to her newsletters: Between the Lines and Where the Shadows Linger!And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:SimpliSafe: 50% off + 1st month free: simplisafe.com/jordanAirbnb: airbnb.com/hostApretude: Apretude.com or call 1-888-240-034Quiltmind: Email jordanaudience@quiltmind.com to get started or visit quiltmind.com for more infoWhat Was That Like: Listen here or wherever you find fine podcasts!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In today's episode of Barbell Shrugged, Anders, Doug, and Travis dive into Coach Travis' recent melanoma diagnosis, how he found out about it, and his recent surgery to eliminate it. We also dive into Anders' quest to build a gym in the middle of the woods where he plans on lifting giant trees and the latest in strength tech with Travis Mash. Work With Us: Arétē by RAPID Health Optimization Links: Anders Varner on Instagram Doug Larson on Instagram Coach Travis Mash on Instagram

In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma. We covered a wide range of topics, including: •⁠  ⁠The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation. •⁠  ⁠The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients. •⁠  ⁠Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808. •⁠  ⁠The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring. •⁠  ⁠The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors. Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights! #Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers

Today's guest is Kevin Donaghy, stage IV Melanoma survivor and author of Stories of Cancer and Hope, a collection of honest stories from people directly affected by cancer. He works with several cancer charities in the UK, donating thousands of copies of the book as well as proceeds from the sale of the book.We talk about Stage IV cancer, finding community and hope through shared stories, silver linings and new beginnings amidst cancer, advancements in immunotherapy and cancer research, and so much more!Resources:Kevin's Website: https://storiesofcancerandhope.co.uk/Kevin's LinkedIn: https://www.linkedin.com/in/kdonaghy/Kevin's Instagram: https://www.instagram.com/storiesofcancerandhope/Kevin's Facebook: Kevin DonaghyKevin's X: https://x.com/storiesofc62048Stories of Cancer and Hope Book on AmazonFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Dr. Aideen McInerney-Leo explores hereditary melanoma (CDKN2A), diagnostic disclosure in Turner syndrome, mainstreaming genomics, gene therapy, and the expanding role of genetic counsellors in research and patient care. Through clinical stories, family perspectives and practical takeaways on testing and screening, this episode highlights how research and clear communication improve outcomes — with a personal note on the therapeutic craft of bead-making.

No one's buying ABC's excuse about canning Jimmy Kimmel any more than anyone is buying Kash Patel's "Tyler Robinson text messages." Both are equally absurd. Nitwit Nero gets a very special salute in a royal review.  Melanoma, meanwhile is just . . . weird in her Grim Reaper getup. Was she rehearsing wearing widow's weeds? CNN provides a mixed bag on Jimmy Kimmel. There was almost some scant journalism. 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

Julie Howle is a talented triathlete and surgical oncologist.She's currently the Head of the Melanoma and Sarcoma Multidisciplinary Groups at Westmead Hospital here in Sydney and a Clinical Senior Lecturer at The University of Sydney.Julie is also an Age Group World Champion triathlete, having won her AG at the ITU Long Distance World Championships in 2017. And she's a 2x finisher for the Hawaii Ironman in Kona (in 2017 and 2018).Plus she's someone who openly admits that her experience of changing degrees at University “laid the foundation for a lifetime of the imposter syndrome”.Julie and I discuss:- how being resilient and focusing on her goals has helped her navigate her experience with the Imposter Complex,- how the words “World Champion” sit with her,- why she took almost 10 years from her first triathlon to do her first Ironman,- why being sick in the week leading up to her 1st Hawaii Ironman at Kona was a good thing,- how she's realised getting stuck in ‘comparison' ruins her enjoyment of the sport,- how she (as a melanoma specialist living here in Australia, a country with one of the highest rates of skin cancer) protects her skin from the sun while training and racing, and- what you need to do to protect and monitor your skin.Julie is such a softly spoken, humble and genuinely lovely woman. I hope you enjoy this conversation as much as I did.

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

Interview with David C. Whiteman, MBBS, PhD, author of A Risk Prediction Tool for Invasive Melanoma. Hosted by Adewole S. Adamson, MD. Related Content: A Risk Prediction Tool for Invasive Melanoma

The incidence and prevalence of cutaneous melanoma in the US and worldwide have increased over the last 5 decades. JAMA Review Author John Kirkwood, MD, discusses the epidemiology, risk factors, treatment, and prevention of melanoma with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Cutaneous Melanoma ----------------------------------- JAMA Editors' Summary